Document Detail

Prasugrel (Effient) vs. clopidogrel (Plavix).
MedLine Citation:
PMID:  19738549     Owner:  NLM     Status:  MEDLINE    
The FDA has approved prasugrel (Effient--Lilly/Daiichi Sankyo), an oral antiplatelet drug, for use with aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndromes (ACS) being managed with percutaneous coronary intervention (PCI).1 It will compete with clopidogrel (Plavix) for such use.
Related Documents :
19804099 - Clopidogrel plus aspirin in patients with acute myocardial infarction treated with fibr...
9627529 - The efficacy and safety of combination warfarin and asa therapy: a systematic review of...
10639269 - The essence trial: efficacy and safety of subcutaneous enoxaparin in unstable angina an...
12052269 - Glycoprotein receptor inhibitors in the management of acute coronary syndromes.
2109459 - Disseminated intravascular coagulation and myocardial infarction in a haemophilia b pat...
17223419 - Usefulness of routine unfractionated heparin infusion following primary percutaneous co...
7398389 - M-mode echocardiography in anteroseptal myocardial infarction. lack of sensitivity.
6160509 - Implantation of atrial synchronous pacemaker with transvenous electrodes after surgery ...
1820299 - Can angiotensin converting enzyme (ace) inhibitors influence the risk of sudden cardiac...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Medical letter on drugs and therapeutics     Volume:  51     ISSN:  1523-2859     ISO Abbreviation:  -     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-09     Completed Date:  2009-09-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985240R     Medline TA:  Med Lett Drugs Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  69-70     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Approval / methods
Piperazines / adverse effects,  economics,  pharmacology,  therapeutic use*
Platelet Aggregation Inhibitors / adverse effects,  economics,  pharmacology,  therapeutic use*
Randomized Controlled Trials as Topic / methods
Thiophenes / adverse effects,  economics,  pharmacology,  therapeutic use*
Ticlopidine / adverse effects,  analogs & derivatives*,  economics,  pharmacology,  therapeutic use
United States
Reg. No./Substance:
0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Thiophenes; 0/prasugrel; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Primary care in the ED - Why?
Next Document:  Calcitriol (Vectical) for mild to moderate plaque psoriasis.